What DuoVisc Provisc treats: main uses and benefits

DuoVisc ProVisc is commonly used as a specialized support agent to manage the physical risks and instabilities inherent to intraocular surgery, which is the clinical context in which its benefits are applied. As officially classified for clinical use, this device provides crucial mechanical support to the surgical environment, assisting with procedures like cataract extraction and intraocular lens implantation.

This material is relevant in clinical settings involving the heightened vulnerability of tissues, notably the corneal endothelium, to potential trauma. Its use is applied when temporary structural stabilization and space maintenance within the anterior chamber are required. It provides support that helps preserve the integrity of these crucial structures.

Quick Fact

Supports Management During Surgical Stress This agent assists in minimizing physical trauma and structural instability during key phases of the eye procedure.

---

Shielding of Delicate Eye Tissues

This agent is applied in situations involving the potential for physical trauma to the eye's internal structures during the operation. It provides support that contributes to the preservation of these tissues. This supportive action may help preserve a structure essential for visual function.

Stabilizing the Surgical Field

The material is relevant in contexts requiring temporary structural stabilization and space maintenance within the anterior chamber, helping to counteract instability relevant when performing micro-surgical steps. The support provided contributes to the general goal of a stabilized surgical environment.

Regulatory References

1. FDA Devices@FDA summary

Eligibility Map: Who Can and Cannot Use DuoVisc Provisc

The eligibility profile for DuoVisc Provisc is determined by its classification as an Ophthalmic Viscosurgical Device (OVD), a temporary, non-systemic aid used exclusively during eye surgery. This status eliminates the need for many systemic restrictions common to absorbed medicines.

---

Eligibility Scope

Classification	Population/Condition
Use is Allowed	Patients undergoing anterior segment ophthalmic surgery, specifically cataract extraction and intraocular lens (IOL) implantation (use is established in adults/older adults).
Use is Contraindicated	Patients with a known hypersensitivity or allergy to sodium hyaluronate or any other component of the Provisc OVD formulation.
Use Requires Precaution	Patients with pre-existing Ocular Hypertension or Glaucoma are eligible but require careful postoperative monitoring due to the risk of temporary intraocular pressure spikes.
Use Not Established	Pediatric patients; specific safety and efficacy data are not established in the regulatory labeling for this age group, though use is not formally prohibited.
Systemic Restrictions	None documented. Restrictions based on systemic organ function (e.g., hepatic or renal impairment) are not applicable to this non-systemic device.

---

Eligibility Summary

Official regulatory documents define eligibility based on the surgical necessity of the procedure and the patient's allergy status. The only absolute exclusion is a known hypersensitivity to the device's components. Use is established in the general adult population requiring the specified surgery, while use in pediatric patients is considered not established.

The official interaction profile for DuoVisc ProVisc is highly restricted because the product is classified as an Ophthalmic Viscosurgical Device (OVD) designed for transient, non-systemic use during surgery. The interaction structure is defined by a distinct physicochemical incompatibility rather than standard metabolic pathways.

Incompatibility with Quaternary Ammonium Salts

Officially documented information states that DuoVisc ProVisc is strictly incompatible with solutions containing quaternary ammonium salts, specifically including preservatives such as Benzalkonium Chloride (BAC). This incompatibility is crucial because contact between the sodium hyaluronate material and these substances results in a precipitate—a physical reaction that causes clouding or aggregation. This constraint dictates a procedural restriction in the immediate surgical environment: solutions containing Benzalkonium Chloride must not be used for ocular irrigation while the sodium hyaluronate material is present in the anterior chamber. This constitutes a mandatory timing separation requirement to prevent compromise of the surgical field.

Absence of Systemic Interactions

Consistent with its temporary, localized action, regulatory documentation confirms no known systemic drug–drug interactions. This includes an absence of interactions mediated by metabolic enzymes (such as CYP450) or drug transporters. Furthermore, no interactions with food, alcohol, supplements, or herbal products are documented in the official labeling. The product is not associated with pharmacodynamic interactions that would alter the effects of systemically administered medications.

How DuoVisc Provisc Works: Mechanism of Action

The DuoVisc system achieves its effect through the physical and mechanical modulation of the eye's anterior chamber, operating in two distinct mechanistic domains using its separate components.

The cohesive component (ProVisc) contains high molecular weight sodium hyaluronate, and its mechanism is based on its high viscosity and elasticity. This creates a temporary, solid-like mass that resists deformation, allowing it to expand and stabilize the intraocular space. This physical property results in the mechanical stabilization of the intraocular volume.

Conversely, the dispersive component (Viscoat) contains sodium hyaluronate and chondroitin sulfate, whose molecular properties promote strong adhesion to ocular tissues, such as the corneal endothelium. This mechanism establishes a physical, protective barrier layer that shields these delicate cells from mechanical trauma and fluid-induced stress. This direct physical shielding contributes to the maintenance of the mechanical integrity of internal eye tissues.

Administration Protocol: DuoVisc Provisc

DuoVisc Provisc is officially designated as an Ophthalmic Viscosurgical Device (OVD) and its usage is limited to the intraoperative setting for anterior segment procedures, such as cataract extraction and intraocular lens (IOL) implantation. The administration protocol focuses on the method of delivery, necessary volume, and mandatory post-operative handling.

---

Administration Scope

Feature	Official Labeled Instruction
Route of administration	Intraocular use via intracameral injection into the anterior chamber. The solution may also be used to coat surgical instruments or the IOL prior to implantation.
Dosing schedule	A sufficient amount is injected slowly and carefully to maintain space and facilitate surgical manipulation. The final volume used is procedure-dependent, and additional material may be injected to replace volume lost during the operation.
Preparation requirements	The material, which is supplied in pre-filled syringes (0.4 mL or 0.55 mL volumes), must be stored in a refrigerator (2 C to 8 C) but must be allowed to reach room temperature prior to administration.

---

Procedural Structure and Duration

The Provisc component is for single use only and is administered intraoperatively, typically before or after removal of the crystalline lens. For injection, the syringe must be assembled with a provided cannula, such as a 27 gauge. The material is intended for temporary use within the eye; established protocols require that the viscoelastic material must be removed completely from the eye by thorough irrigation and/or aspiration at the close of surgery to conclude the procedure's use protocol. No specific dose adjustments are detailed in the official labeling based on patient age or organ function.

Research Evidence / Overview of Studies for DuoVisc Provisc

Evidence Supporting Use as a Surgical Aid

Research has explored whether DuoVisc Provisc, as the cohesive agent of the DuoVisc system, was associated with outcomes relevant to Ophthalmic Viscosurgical Devices (OVDs) during routine intraocular procedures. This was primarily investigated through Randomized Controlled Trials (RCTs), supplemented by systematic reviews. The evidence contributes to the broader evidence landscape by comparing the use of the DuoVisc system against other single and dual OVDs. Research examined measurements related to the preservation of delicate structures within the eye during the operational steps.

Comparative studies monitored physical changes that may occur in the eye following surgery. Researchers primarily monitored the Endothelial Cell Density (ECD), which is a key measure of the health of the back layer of the cornea, by checking the percentage loss of these cells compared to measurements taken before the surgery. Studies also monitored measurements of Central Corneal Thickness (CCT) and tracked Intraocular Pressure (IOP) in the immediate hours and days following the procedure. Findings report patterns observed in the studies related to these corneal health measurements over the observed time intervals.

Primary Focus of Comparative Trials

The main focus of research examined outcomes related to anterior chamber space maintenance and intraocular tissue stability during the critical phases of surgery. Studies monitored the agent’s specific physical properties (its high cohesiveness) and how this relates to its studied cohesive action. Studies monitored surgeon reports regarding the material’s physical characteristic that facilitated removal after the procedure was complete. These findings help contextualize the measured outcomes associated with the material during the operation.

Duration of Research and Long-Term Follow-up

The clinical research that served as the basis for regulatory evaluation typically involved short to intermediate-term follow-up periods. Structural measures like endothelial cell loss were commonly tracked up to three months post-surgery. Long-term effects are not fully established with the same certainty as the short-term outcomes. Evidence remains limited regarding the durability of structural preservation beyond the intermediate three-month observation period that was commonly used in the primary comparative trials.

Evidence in Specific Patient Groups

The primary studies focused on Adults and Older Adults undergoing routine cataract procedures, generally involving populations without significant pre-existing eye diseases. Consequently, data for certain groups remain insufficient. The existing research record describes limited insight into how the material was evaluated when used in surgical contexts involving pre-existing corneal damage or where the patient has complicating eye health factors.

Common questions about DuoVisc Provisc (FAQ)

---

Q: What is DuoVisc Provisc used for?

A: DuoVisc Provisc is an ophthalmic visco-surgical device (OVD) indicated for use during cataract surgery and intraocular lens (IOL) implantation. According to official product information, it is used to assist in preserving eye tissues and maintaining the necessary space during the procedure. The product is composed of two components: Viscoat and Provisc.

---

Q: How is DuoVisc Provisc different from other similar products?

A: Regulatory documents state that DuoVisc Provisc is a Dual Pack Viscoelastic System. This means it is designed to be used sequentially, applying the Viscoat component first for high protection and then the Provisc component for space maintenance and tissue manipulation during surgery. This dual-pack structure is how the product is designed to be used during the procedure.

---

Q: Is DuoVisc Provisc designed to be left in the eye after surgery?

A: The product information indicates that DuoVisc Provisc is not designed to remain in the eye. It is intended as a surgical aid and is designed to be removed from the eye following the completion of the surgical procedure, rather than being an implant left in long-term.

---

Q: Can DuoVisc Provisc be used if a patient has a known allergy to any of its ingredients?

A: According to the official product information, DuoVisc Provisc is contraindicated (should not be used) in patients with known hypersensitivity (severe allergic reaction) to any component of the Viscoat or Provisc formulation. This information is provided in the contraindication section of the product labeling.

---

Q: What are the risks if the product is not completely removed after surgery?

A: Studies and official information indicate that any material left in the eye after the procedure may increase intraocular pressure (IOP), which is the fluid pressure inside the eye. For this reason, official information emphasizes that complete removal of the viscoelastic device following IOL implantation is required to minimize the risk of increased pressure.

Storage and Disposal of DuoVisc Provisc

Storage and disposal requirements for DuoVisc Provisc are strictly defined to maintain the sterility and quality of this Ophthalmic Viscosurgical Device.

---

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Must be stored under refrigerated conditions between 2 C and 8 C (36 F to 46 F).
Protection	Must be protected from freezing and protected from light.
Packaging	Do not use if the sterile blister pack is opened or damaged.
Pre-use Handling	The refrigerated product should be allowed to reach room temperature prior to use.

---

Disposal Instructions

This is a single-use sterile device. Unused or contaminated equipment must be disposed of using applicable safe disposal procedures. Disposal must comply with laws and regulations governing the handling and discarding of biohazardous materials.